ʻO Ruxolitinib kahi mole liʻiliʻi ʻo Janus kinase inhibitor i hoʻohana ʻia i ka mālama ʻana i ka myelofibrosis waena a kiʻekiʻe paha a me nā ʻano kūʻokoʻa o ka polycythemia vera a me ka maʻi graft-vs-host.Hoʻopili ʻia ʻo Ruxolitinib me nā kiʻekiʻe liʻiliʻi a maʻamau i ka serum aminotransferase i ka wā o ka mālama ʻana a me nā manawa liʻiliʻi o ka hōʻeha ʻana iā ia iho, ʻike ʻia i ka maʻi idiosyncratic acute ate a me nā hihia o ka hoʻihoʻi ʻana o ka hepatitis B i nā poʻe maʻi.

ʻO Ruxolitinib kahi mea hoʻopaneʻe kinase pili i ka Janus-associated kinase (JAK) me nā hana antineoplastic a me nā hana immunomodulating.Hoʻopaʻa pono ʻo Ruxolitinib a kāohi i ka proteintyrosinekinases JAK 1 a me 2, hiki ke alakaʻi i ka hōʻemi ʻana i ka mumū a me ka pale ʻana i ka hoʻonui ʻana o ka cellular.ʻO ke ala JAK-STAT (signal transducer and activator of transcription) he mea nui i ka hōʻailona o nā cytokines he nui a me nā mea ulu a pili i ka hoʻonui ʻana o ka cellular, ulu, hematopoiesis, a me ka pane ʻana;Hiki ke hoʻoponopono ʻia nā kinase JAK i nā maʻi ʻeha, nā maʻi myeloproliferative, a me nā maʻi ʻino like ʻole.

ʻO Ruxolitinib kahipyrazoleua pani ʻia ma ke kūlana 1 e kahi hui 2-cyano-1-cyclopentylethyl a ma ke kūlana 3 e kahi hui pyrrolo [2,3-d] pyrimidin-4-yl.Hoʻohana ʻia e like me ka paʻakai phosphate no ka mālama ʻana i nā maʻi me ka myelofibrosis waena a kiʻekiʻe paha, me ka myelofibrosis mua, post-polycythemia vera myelofibrosis a me post-essential thrombocythemia myelofibrosis.He kuleana kona ma ke ʻano he antineoplastic agent a me kahi EC 2.7.10.2 (ʻaʻole kikoʻī protein-tyrosinekinase) mea pale.He nitrile ia, apyrrolopyrimidinea he lālā o nā pyrazoles.